Clinical review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tafamidis meglumine 80 mg for the treatment of adult patients with cardiomyopathy due to wild-type or hereditary transthyretin-mediated amyloidosis (hATTR)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, April 2020
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tafamidis meglumine 80 mg for the treatment of adult patients with cardiomyopathy due to wild-type or hereditary transthyretin-mediated amyloidosis (hATTR) |
|---|---|
| Item Description: | "Final (with redactions)." |
| Physical Description: | 1 PDF file (80 pages) |